Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115245 · ClinicalTrials.gov registry record · Phase 3
Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00115245: Completed Phase 3 study, sponsored by Novartis.
NCT00115245 is a Phase 3 study that has completed, run by Novartis. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00115245, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
This research study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (telbivudine) versus adefovir dipivoxil, a drug approved by the Food and Drug Administration (FDA) for the treatment of hepatitis B infection. The results for patients taking LdT will be compared to results for patients taking adefovir dipivoxil.
Interventions
- DRUG Telbivudine (LdT)
- DRUG Adefovir Dipivoxil
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-11 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
What the finished NCT00115245 record still lists
NCT00115245 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which Telbivudine (LdT) is the first listed.
NCT00115245 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00115245 about?
NCT00115245 is a clinical study titled "Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B". This research study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (telbivudine) versus adefovir dipivoxil, a drug approved by the Food and Drug Administration (FDA) for the treatment of hepatitis B infection. The results for patients taking LdT wil...
What is the current status of trial NCT00115245?
This trial is currently completed. It is a Phase 3 study. The study started on 2004-11. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00115245?
The interventions under investigation include: Telbivudine (LdT) (DRUG), Adefovir Dipivoxil (DRUG).
Who is sponsoring clinical trial NCT00115245?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia